Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H34N4O5S.H3O4P |
| Molecular Weight | 600.621 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OP(O)(O)=O.COC1=CC(C)=C(C(C)=C1)S(=O)(=O)N(C)CCOCC(=O)N(C)CC2=CC=C(C=C2)C3=NCCN3
InChI
InChIKey=RMWOBELGMBYWEZ-UHFFFAOYSA-N
InChI=1S/C25H34N4O5S.H3O4P/c1-18-14-22(33-5)15-19(2)24(18)35(31,32)29(4)12-13-34-17-23(30)28(3)16-20-6-8-21(9-7-20)25-26-10-11-27-25;1-5(2,3)4/h6-9,14-15H,10-13,16-17H2,1-5H3,(H,26,27);(H3,1,2,3,4)
Safotibant (previously known as LF22-0542) was developed as an antagonist at bradykinin B1 receptor for the topical treatment of diabetic macular edema. This drug participated in phase II clinical trials in Australia, in Belgium and in the Czech Republic. However, further, development was discontinued.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Ocular application of the kinin B1 receptor antagonist LF22-0542 inhibits retinal inflammation and oxidative stress in streptozotocin-diabetic rats. | 2012 |
|
| Role of kinin B1 and B2 receptors in a rat model of neuropathic pain. | 2008-02 |
|
| Antinociceptive pharmacology of N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl) sulfonyl]methylamino]ethoxy]-N-methylacetamide, fumarate (LF22-0542), a novel nonpeptidic bradykinin B1 receptor antagonist. | 2006-07 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Y0VL627968
Created by
admin on Mon Mar 31 20:06:14 GMT 2025 , Edited by admin on Mon Mar 31 20:06:14 GMT 2025
|
PRIMARY | |||
|
1380572-99-5
Created by
admin on Mon Mar 31 20:06:14 GMT 2025 , Edited by admin on Mon Mar 31 20:06:14 GMT 2025
|
PRIMARY | |||
|
71587994
Created by
admin on Mon Mar 31 20:06:14 GMT 2025 , Edited by admin on Mon Mar 31 20:06:14 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
